Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Gains from Sales and Divestitures (2022 - 2026)

Compass Therapeutics' Gains from Sales and Divestitures history spans 5 years, with the latest figure at $284000.0 for Q1 2026.

  • On a quarterly basis, Gains from Sales and Divestitures fell 65.49% to $284000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $284000.0, a 65.49% decrease, with the full-year FY2025 number at $1.1 million, up 104.38% from a year prior.
  • Gains from Sales and Divestitures hit $284000.0 in Q1 2026 for Compass Therapeutics, down from $1.1 million in the prior quarter.
  • Over the last five years, Gains from Sales and Divestitures for CMPX hit a ceiling of $1.1 million in Q4 2025 and a floor of $225000.0 in Q1 2024.
  • Historically, Gains from Sales and Divestitures has averaged $511454.5 across 5 years, with a median of $300000.0 in 2022.
  • Biggest five-year swings in Gains from Sales and Divestitures: soared 265.78% in 2025 and later tumbled 65.49% in 2026.
  • Tracing CMPX's Gains from Sales and Divestitures over 5 years: stood at $300000.0 in 2022, then changed by 0.0% to $300000.0 in 2023, then soared by 75.0% to $525000.0 in 2024, then skyrocketed by 104.38% to $1.1 million in 2025, then crashed by 73.53% to $284000.0 in 2026.
  • Business Quant data shows Gains from Sales and Divestitures for CMPX at $284000.0 in Q1 2026, $1.1 million in Q4 2025, and $823000.0 in Q3 2025.